Reports Q3 revenue $2.4M, consensus $1.31M.Following DBV’s request for clarification after receipt of Type C Meeting feedback in July 2023, the FDA provided Written Responses on protocol design elements for the COMFORT supplemental safety studies. Both COMFORT Toddlers and COMFORT Children protocol will have harmonized language guiding how the product will be used in the trials, such as, “Each DBV712 250 microgram epicutaneous system is intended to be worn for a full day .” These instructions are simpler and more concise relative to previously used protocol language. Further to this approach, both supplemental safety studies will seek to enroll populations that are closely aligned with their respective Phase 3 efficacy studies, as is feasible. For COMFORT Toddlers, eligibility criteria will be the same as in EPITOPE as reliance on peanut specific-IgE and skin prick test alone does not ensure a Regulatory-level of assurance of peanut allergy or a similar peanut allergic patient population relative to EPITOPE. Thus, COMFORT Toddlers will include a double-blind, placebo-controlled food challenge as part of the Inclusion criteria.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DBVT:
- DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results
- DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
- DBV Technologies appoints Virginie Boucinha as CFO
- DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
- Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023